RSV Vaccine Indications: Age-Based Clarification
All three RSV vaccines are indicated to prevent lower respiratory tract disease in individuals aged 60 years and older, NOT all three for high-risk individuals aged 18-59 years.
Key Distinction Between the Three Vaccines
The critical difference lies in the specific FDA-approved indications for each vaccine:
Vaccines Approved for Ages ≥60 Years (All Three)
- Arexvy (GSK/RSVPreF3): Approved for adults ≥60 years 1, 2
- Abrysvo (Pfizer/RSVpreF): Approved for adults ≥60 years 1, 2
- mResvia (Moderna/mRNA-1345): Approved for adults ≥60 years 1, 2
Extended Indication for Younger High-Risk Adults (Only ONE Vaccine)
Only Arexvy (RSVPreF3) has an expanded indication for adults aged 50-59 years at increased risk for RSV disease 2. The other two vaccines (Abrysvo and mResvia) do not have this indication for younger high-risk adults.
Clinical Implications
The first statement is correct: All three vaccines share the common FDA indication for prevention of RSV-associated lower respiratory tract disease in adults aged ≥60 years 1, 2.
The second statement is incorrect: Only one vaccine (Arexvy) extends to high-risk individuals in the 50-59 age range, and none are indicated for the 18-59 age bracket mentioned in the question 2.
Current CDC Recommendations (2024 Update)
The Advisory Committee on Immunization Practices now recommends 1:
- All adults ≥75 years: Single dose of any FDA-approved RSV vaccine
- Adults 60-74 years at increased risk: Single dose if they have conditions increasing severe RSV disease risk
- Previous recipients: Should not receive another dose
Common Pitfall to Avoid
Do not confuse vaccine indications (FDA-approved age ranges) with recommendations (CDC guidance on who should receive vaccination). While Arexvy has an indication down to age 50 for high-risk individuals, current CDC recommendations focus on ages 60 and above, with risk stratification for the 60-74 age group 1.